An Experimental Drug Manages to Reduce Acute Leukemia in 18 Patients

An experimental drug for advanced or resistant acute myeloid leukemia has achieved, in a small clinical trial, some degree of remission in 53% of patients and completes in 30% (18 people), although possible signs of resistance to treatment have also been detected.